- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00331357
Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire
The objective of this study is to describe a paediatric population presenting an acute idiopathic thrombocytopenic purpura (ITP) and their evolution during their therapy in the region Pays de la Loire. The study will particularly evaluate the quality of life of these patients and their parents.
The secondary objectives are to identify the predictive factors of the complications, the repetitions and the chronicity of the ITP, to estimate the principal parameters of the economic cost of therapy of the children suffering from ITP according to the protocol of therapy, set up in the region Pays de la Loire and the constitution of a blood sample collection which allow a better understanding of the physiopathology of this disease.
It is about a prospective, multicentric clinical epidemiologic study of a paediatric cohort. Patients: 100 children from 0 to 17,99 years suffering from a first discovered ITP. The patients are not included if they present a serious, intercurrent, stabilized chronic pathology or not likely to modify the quality of life of the child and if they present a pathology other than the thrombopenia bringing into play the vital prognosis within a time lower than one year. These patients will be followed for 6 months according to the diagnosis of their ITP.
During the 6 months follow-up of each patient, the study will not carry out more consultations, nor more blood tests than the usual follow-up of a child suffering from ITP. On the other hand, in addition to the J0 questionnaire, it will be requested to the patient and to his family to fill in the questionnaires of quality of life and way of life during the consultations of J8, 1 month, 3 months and 6 months. A check-up of autoimmunity at 6 months will be carried out if the thrombopenia persists (this check-up is usual and not-specific to the study). At the time of the blood test for the control of the platelets at J0 and 6 months, an additional blood sample will be carried out: 5 ml are taken for the children of an age ≤ at 2 years, 10 ml from 2 to 4 years and 15 ml of blood for the children of an age > at 4 years. These blood samples are intended for the constitution of a blood sample collection.
The protocol of therapy of the children suffering from ITP is homogeneous in all centers, this protocol being a consensus established by the network of Oncopaediatrics of the Pays de la Loire. The instituted treatment will be in function of the gravity of the ITP expressed in 4 stages:
Stage I: Platelets > 20 gigas/L and absence of clinical signs. Stage II: Platelets > 10 gigas/L and hemorrhagic signs: haematomas, petechias or occasional epistaxis without repercussion on the daily life.
Stage III: moderate. Platelets > 10.000/mm3 and epistaxis with gauze pluggings or mucous lesions.
Stage IV: severe. Platelets ≤ 10.000/mm3 or fall of 2 grs/dl of haemoglobin with bleedings: epistaxis, melaena or haemorrhages requiring a blood transfusion or an hospitalization and important changes in the activities of the daily life.
Stages I and II do not receive any treatment and benefit from a simple monitoring.
Stages III benefit from either a corticosteroid treatment (Méthylprednisolone or Prednisone) at the dose of 4 mg/kg and per day in 2 intervals during 4 days (maximal dose of 100 mg/day) or a monitoring according to the appreciation of the clinician.
Stages IV profit in first intention from a treatment by Méthylprednisolone or Prednisone at the dose of 4 mg/kg and per day in 2 intervals during 4 days (maximal dose of 100 mg/jour).
The therapeutic attitude and the stadification belong to a regional consensus, established before the study, but each one can decide to apply a treatment according to the gravity of the clinical state of the child.
연구 개요
상태
연구 유형
등록
연락처 및 위치
연구 연락처
- 이름: Isabelle PELLIER, MD
- 이메일: Ispellier@chu-angers.fr
연구 장소
-
-
-
Angers, 프랑스, 49933
- UH of Angers
-
연락하다:
- Isabelle PELLIER, MD
- 이메일: Ispellier@chu-angers.fr
-
부수사관:
- Xavier RIALLAND, MD
-
부수사관:
- Petronella RACHIERU, MD
-
부수사관:
- Estelle DARVIOT, MD
-
Cholet, 프랑스, 49 325
- Hospital of Cholet
-
연락하다:
- Guy SEGUIN, MD
- 이메일: guy.seguin@ch-cholet.fr
-
수석 연구원:
- Guy SEGUIN, MD
-
부수사관:
- Francis CHOMIENNE, MD
-
부수사관:
- Sylvaine POIGNANT, MD
-
부수사관:
- Catherine RADET, MD
-
부수사관:
- Valérie COURTIN, MD
-
부수사관:
- Isabelle GRIMAL, MD
-
La Roche Sur Yon, 프랑스, 85 925
- Hospital of La Roche Sur Yon
-
연락하다:
- Nathalie GUILLEY, MD
- 이메일: nathalie.guilley@chd-vendee.fr
-
수석 연구원:
- Nathalie GUILLEY, MD
-
부수사관:
- Dominique MEDINGER, MD
-
Laval, 프랑스, 53 015
- Hospital of Laval
-
연락하다:
- Joachim BASSIL, MD
- 이메일: joachim.bassil@chlaval.fr
-
수석 연구원:
- Joachim BASSIL, MD
-
부수사관:
- Eric PARIS, MD
-
Le Mans, 프랑스, 72 037
- Hospital of Le Mans
-
연락하다:
- Eliane TARRAL, MD
- 이메일: etarral@ch-lemans.fr
-
수석 연구원:
- Elaine TARRAL, MD
-
부수사관:
- Marie-Chantal CHEVALLIER, MD
-
Nantes, 프랑스, 44 093
- UH of Nantes
-
수석 연구원:
- Caroline Thomas, MD
-
부수사관:
- Françoise MECHINAUD, MD
-
Saint Nazaire, 프랑스, 44 606
- Hosptal of Saint Nazaire
-
연락하다:
- Arnaud BOUTET, MD
- 이메일: a.boutet@ch-saintnazaire.fr
-
수석 연구원:
- Arnaud BOUTET, MD
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- children 0 to 17,99 years
- suffering from a first discovered ITP
Exclusion Criteria:
- serious, intercurrent, stabilized chronic pathology or not likely to modify the quality of life of the child
- pathology other than the thrombopenia bringing into play the vital prognosis within a time lower than one year
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
공동 작업자 및 조사자
수사관
- 연구 책임자: Isabelle PELLIER, MD, UH of Angers
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작
연구 완료
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- PHRC-05-06
- CCPPRB : 2006/04
- DGS : 2006/0212
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .